Name | N-[(3-benzamidophenyl)carbamothioyl]-3,4,5-trimethoxybenzamide |
---|---|
Synonyms |
N-[[[3-(benzoylamino)phenyl]amino]thioxomethyl]-3,4,5-methoxy-benzamide
Immethridine dihydrobromide MRT-10 N-(3-benzamidophenylcarbamothioyl)-3,4,5-trimethoxybenzamide |
Description | MRT-10 is a seven-transmembrane receptor smoothened (Smo) antagonist with an IC50 of 0.65 μM in the micromolar range in various Hedgehog (Hh) assays. MRT-10 binds to the Smo receptor at the level of the Bodipycyclopamine binding site. MRT-10 can be used for the research of cancer[1][2]. |
---|---|
Related Catalog | |
In Vitro | MRT-10 inhibits the Smo-induced IP accumulation in a dosedependent manner (IC50=2.5 μM) in HEK293 cells[1]. MRT-10 (10-9-10-5 M; 2 h) blocks Bodipy-cyclopamine (5 nM; 2 h) binding to cells expressing mouse Smo in a dosedependent manner with an IC50=0.5 μM[1]. MRT-10 (10-9-10-5 M; 40 h) inhibits ShhN signaling in Shh-light2 cells in a dose-dependent manner with an IC50=0.64 μM[1]. MRT-10 (10-9-10-5 M; 6 days) inhibits the SAG-induced (0.1 μM) alkaline phosphatase (AP) activity with an IC50=0.90 μM ) in C3H10T1/2 cells[1]. |
References |
Molecular Formula | C24H23N3O5S |
---|---|
Molecular Weight | 465.52200 |
Exact Mass | 465.13600 |
PSA | 144.03000 |
LogP | 5.27080 |
Symbol |
GHS05, GHS09 |
---|---|
Signal Word | Danger |
Hazard Statements | H318-H410 |
Precautionary Statements | P273-P280-P305 + P351 + P338-P501 |
RIDADR | UN 3077 9 / PGIII |